First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma
Clinical Lymphoma, Myeloma & Leukemia（2023）
关键词
relapsed/refractory multiple myeloma,venetoclax,carfilzomib-dexamethasone,carfilzomib-dexamethasone
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要